Introduction
Antibiotic therapy and emerging resistance are dynamic processes in constant evolution. Penicillin resistance of Streptococcus pneumoniae has been increasing worldwide during the last two decades. Since this bacterium plays a major role in respiratory tract infections, empirical antibiotic therapy has to be adapted to the local geographical resistance pattern. Macrolide resistance is also increasing particularly in certain European countries. 1 In a recent Canadian survey, a marked increase in the occurrence of resistance to erythromycin was also found, rising from 1.2% in 1988 to 5.3% in 1996. 2 Currently available quinolones do not have excellent invitro activity against S. pneumoniae, so their use in respiratory tract infections is thus restricted to certain clinical conditions. Because of the extent of multiple antibiotic resistance in S. pneumoniae, 3 new therapeutic alternatives are needed. New quinolones such as trovafloxacin and Bay 12-8039 have been reported to have enhanced activity compared with older quinolones against S. pneumoniae. Data evaluating the in-vitro activity of these agents against S. pneumoniae are available, 4, 5 but no study comparing these quinolones has yet been published. As levofloxacin is now available in North America, its activity was compared with that of the two others.
Materials and methods
The principal aim of this study was to determine and compare the in-vitro activities of four quinolones (ciprofloxacin, levofloxacin, trovafloxacin, Bay 12-8039) and cefuroxime against clinical isolates of S. pneumoniae. Another objective was to determine the in-vitro activity of newer and older quinolones with regard to the level of penicillin resistance among S. pneumoniae strains.
Isolates
Four hundred and fifty-two single clinical isolates of S. pneumoniae isolated in our institution from 1989 to 1997 were tested in this study; of the 452 isolates, 288 (64%) were invasive, originating from either blood or CSF, while 164 (36%) were isolated from the respiratory tract.
Antibiotics
Penicillin, cefuroxime and ciprofloxacin were purchased from Nucrotechnics (Scarborough, Ontario, Canada). MICs were determined by a broth microdilution method using NCCLS recommendations.
6 A MacFarland 0.5 suspension was prepared from an overnight sheep blood agar culture of S. pneumoniae. This solution was then diluted 1 in 10 to yield 10 7 cfu/mL. Five millilitres of this suspension was added to a cation-adjusted MuellerHinton broth supplemented with 5% lysed horse blood in order to reach a final concentration of 5 10 4 cfu/well. Trays were incubated at 35ºC for 24 h in air. The lowest concentration of antibiotic showing no growth was read as the MIC. S. pneumoniae ATCC 49619 was used as a control strain.
Results and discussion
Trovafloxacin and Bay 12-8039 were much more active against S. pneumoniae than were older quinolones such as ciprofloxacin and levofloxacin (Table I) . Taking all strains into account, MIC 90 s of trovafloxacin and Bay 12-8039 were four or five two-fold dilutions lower than those of levofloxacin and ciprofloxacin. Although cefuroxime was very active against penicillin-susceptible strains, it was considerably less active against penicillin-intermediate and penicillin-resistant strains when compared with trovafloxacin and Bay 12-8039 (Tables I and II) .
The upper breakpoint concentration for susceptibility to cefuroxime was taken as 0.5 mg/L; 6 the cumulative percentage of strains inhibited by that concentration was significantly lower for cefuroxime than for trovafloxacin and Bay 12-8039 (P 0.001) (Table II) . Levofloxacin, the latest quinolone available on the North American market, was slightly more active than ciprofloxacin against penicillin-susceptible S. pneumoniae strains (Table I) , but did not show any significant advantage against intermediate strains (Table I ). In one study evaluating the activity of levofloxacin against bacteraemic isolates of S. pneumoniae, the vast majority of strains had an MIC of 1 mg/L. However, a very large proportion of these strains were penicillin-susceptible. 7 There was no significant difference between trovafloxacin and Bay 12-8039 against S. pneumoniae, both agents showing excellent in-vitro activity even against penicillin-resistant strains. Pharmacokinetic studies in humans have shown that a C max of 4.4 mg/L can be achieved with a 300 mg dose of trovafloxacin, which is about 35 times higher than the MIC 90 of this antibiotic (Table II) .
Using currently available NCCLS criteria, 6 80% of all strains were susceptible to penicillin, 83.6% to cefuroxime and 94% to levofloxacin. Some authors have suggested that antibiotic activity at the 0.12 mg/L concentration is of interest, as the activity of quinolones at concentrations eight times below the susceptible breakpoint may be used to predict the development of resistance during therapy. 5, 8 At this concentration, Bay 12-8039 and trovafloxacin inhibited 92.2% and 90.9% of strains, respectively, while levofloxacin and ciprofloxacin were much less active (Table II) .
This study suggests that new quinolones with much enhanced in-vitro activity against S. pneumoniae could become very useful in the treatment of upper and lower respiratory tract infections. These agents are also known to be active against microorganisms such as Mycoplasma pneumoniae, Legionella spp., Chlamydia pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. 4, 9 Nevertheless, caution should be exercised in the potential excessive use of these antibiotics in the future, as emerging resistance might become the greatest challenge. 
